Anaxomics, member of CataloniaBio & HealthTech, is at the forefront of an innovative project aimed at analysing the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Under the name Project Mathrix, this study, in collaboration with Takeda and a multidisciplinary team of experts, uses virtual patient simulations and Artificial Intelligence techniques to deepen the understanding of ADHD treatments.
The Mathrix Project advances in silico (in-computer) approach to clinical trials, evaluating the efficacy, safety and tolerability of lisdexamfetamine and methylphenidate in virtual patients. In addition, it examines differences in mechanisms of action and responses in different profiles of ADHD patients.
The preliminary results of the study suggest that these two treatments are similar in terms of efficacy and their ability to influence the neuropsychophysiopathological processes of ADHD, but also indicate that they may target different aspects of the disease. Demographic characteristics, such as body mass index and age, could influence the effectiveness of these medications.
The Mathrix Project represents a breakthrough in the application of Artificial Intelligence and pharmacokinetic modelling in personalized medicine. Although the in-silico results need clinical validation, they raise hypotheses that could transform the design of future clinical studies and pave the way for more personalized and effective ADHD treatments.
The achievements of this project have been highlighted in national and international congresses, and the results have been published in renowned scientific journals, including the prestigious journal Frontiers in Psychiatry. Anaxomics and its collaborators continue to advance cutting-edge research to improve the quality of life for people with ADHD.
Related News:
Comments